



Company Announcement

Clinuvel to open Europe office

Melbourne, Australia November 16th 2007

Clinuvel Pharmaceuticals (ASX: CUV; XETRA-DAX: UR9; US ADR: CLVLY) is pleased to announce the expansion of the company's clinical and operational activities. Commencing today, Clinuvel has opened an office in Zurich, Switzerland, to coordinate the extensive clinical trial program currently being conducted in Europe.

With headquarters in Melbourne, Australia, the company now has operational hubs in both San Francisco and Zurich to facilitate the management of the clinical development of CUV1647 across 5 UV and light related indications.

Clinuvel's CEO Dr Philippe Wolgen commented:

"We've expanded Clinuvel into three continents and the Zurich office will play a major role in the commercial development of CUV1647. I am very pleased with the corporate progress that the Clinuvel team has made."

The company is on track to file CUV1647 for its first registration in 2009.

About Clinuvel Pharmaceuticals Limited

Clinuvel Pharmaceuticals Limited (ASX:**CUV**, XETRA/DAX:**UR9**, ADR:**CLVLY**) is an Australian biopharmaceutical company developing its photo-protective drug CUV1647 as a preventative treatment for a range of UV-related skin disorders as well as in cancer related treatments.

The five indications are:

Indication	Description	Clinical Trial Status
Polymorphic Light Eruption (PLE / PMLE)	Sun poisoning	Phase III trials began May 2007
Erythropoietic Protoporphyrin (EPP)	Absolute sun intolerance	Phase III trials began June 2007
Squamous Cell Carcinoma (SCC) and Actinic Keratosis (AK) in organ transplant patients	Non-melanoma skin cancers / precursor to skin cancers	Phase II trials planned to begin 2007
Solar Urticaria (SU)	Acute anaphylactic reaction to sun	Phase II trials planned to begin 2007
Phototoxicity associated with Photodynamic Therapy (PDT)	Photo-sensitivity associated with cancer treatment	Phase II trials planned to begin 2007

Phase I and II human clinical trials using CUV1647 have demonstrated that the drug is well tolerated and no significant safety concerns have been identified to date.

Following successful conclusion of the development program, Clinuvel will work closely with global regulators to facilitate marketing approval of CUV1647.

-END-

For more information contact:

**Mr Darren Keamy
Company Secretary
Clinuvel Pharmaceuticals Limited
Tel: +61 3 9660 4900
investorrelations@clinuvel.com**

Clinuvel is an Australian biopharmaceutical company focussed on developing its leading drug candidate, CUV1647, for a range of UV-related skin disorders resulting from exposure of the skin to harmful UV radiation. Pharmaceutical research and development involves long lead times and significant risks. Therefore, while all reasonable efforts have been made by Clinuvel to ensure that there is a reasonable basis for all statements made in this document that relate to prospective events or developments (forward-looking statements), investors should note the following:

- actual results may and often will differ materially from these forward-looking statements;
- no assurances can be given by Clinuvel that any stated objectives, outcomes or timeframes in respect of its development programme for CUV1647 can or will be achieved;
- no assurances can be given by Clinuvel that, even if its development programme for CUV1647 is successful, it will obtain regulatory approval for its pharmaceutical products or that such products, if approved for use, will be successful in the market place

**Level 11 / 330 Collins Street
Melbourne, Victoria 3000
Australia**

**T +61 3 9660 4900
F +61 3 9660 4999**

clinuvel.com